Scinai Immunotherapeutics changes ADS ratio in move equivalent to 1-for-10 reverse split
SCNI•ADS ratio change and reverse split timing
Scinai Immunotherapeutics will change its ADS-to-ordinary share ratio to 1 ADS for 40,000 shares from 1 for 4,000.
The move takes effect Aug. 21, 2026, equating to a 1-for-10 reverse split of the ADSs.
ADSs are set to trade on Nasdaq on an adjusted basis under SCNI; new CUSIP 09073Q402.
Fractional ADS entitlements will be aggregated and sold, with cash proceeds distributed by the depositary bank.
The company said the objective is to lift the per-ADS price to help regain compliance with Nasdaq’s $1 minimum bid rule.
